ImmunoPrecise
Launches
TATX-112
Candidate
Antibody Program,
for
the
Treatment
of Cancer
and Alzheimer's
Disease
Potential
to
Treat Parkinson's
and Other
Neurodegenerative
Diseases
VICTORIA,
BRITISH
COLUMBIA April 8, 2021 / -- InvestorsHub NewsWire -
IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA")
(NASDAQ: IPA) (TSX VENTURE: IPA)
a leader in full-service, therapeutic antibody
discovery and
development, today announced that its subsidiary
Talem
Therapeutics
LLC
("Talem") has advanced development
of a
candidate panel of vetted, novel, therapeutic
antibodies, collectively referred to as
TATX-112, against an undisclosed
target, into formal
lead
candidate characterization.
It
is
well
documented that certain
genes, when mutated
and
expressed in
different tissues and organs, may play a role in more than
one disease.
Oncology
The target is a protein
receptor
that
is
overexpressed in a variety of
types of
deadly cancers. In
solid
tumors, stimulation of
the
target by its ligand
is described
to result
in activation of
intracellular
signaling pathways that promote cancer cell growth,
survival, invasiveness, metastatic
behavior, and suppress chemotherapeutic
sensitivity of the tumor
cells. Therefore,
interference
with the target signaling is anticipated to
be an attractive approach to induce tumor
suppression, or halting tumor cell
growth. As
current therapies focusing on inhibiting intracellular
target signaling consist
primarily
of
non-target selective small molecule
inhibitors, they may be high risk
for unintentionally causing undesirable
side-effects to the patient
by functionally
blocking related receptor proteins, which are more widely expressed
in the human body, in parallel. In contrast,
Talem
has developed the
TATX-112 antibodies
with the goal
of specifically
blocking the interaction
between the target and its
ligand, e.g. functionally interfering with
the target's biology,
which is
expected to
significantly improve specificity of such tumor therapy due to its relatively
higher expression levels in tumors compared to normal
tissue. That higher specificity
is expected
to increase the therapeutic window by
lowering the potential risk of side effects and positively
impacting
treatment
efficacy. Additionally, the
target's expression profile makes this
membrane protein a promising candidate for antibody-drug
conjugate-based therapies.
Neurodegenerative
Diseases
In addition
to its role
in oncology, the target plays a vital
role in the
nervous system by enhancing neuronal development, survival,
protection, and function. Alzheimer's and other
neurodegenerative diseases are associated with reduced expression
levels of the target and impaired receptor
signaling. Stimulating
intracellular target signaling using agonistic
antibodies is an appealing therapeutic approach to suppress disease
progression with an expectedly higher safety profile than
less-selective small molecules. Such therapeutic strategy requires
blood-brain-barrier passage which can be facilitated by a bi- or
multi-specific antibody format, including an antibody
fragment that induces transport over the blood-brain-barrier upon
binding.
Talem's
Pipeline
As the different clinical
application options for TAXT-112 antibodies require a
functionally
diversified set
of lead
candidates and antibody
format
flexibility, Talem relied on two of IPAs proprietary
target-enrichment
antibody
discovery platforms, B cell Select™ and DeepDisplay™.
Following
selection of both target-reactive B cells from
target
immunized
chicken
and human scFvs from IPA's in-house phage
libraries, 50
sequence-unique
antibodies of particular interest
were prioritized
for more
in-depth characterization
to bin antibodies for further (indication-specific)
clinical development.
In addition to
TATX-112, Talem is continuing development
efforts of its other potential products leveraging its
pipeline of
highly differentiated therapeutic antibody programs for the
potential
treatment
of various
disease areas, including heart
disease,
inflammation, infectious diseases
and
cancer. The Company's
most
advanced
development
program, TATX-03 ("anti-SARS PolyTope"), is a fully
human,
synergistic, antibody cocktail containing potently
neutralizing antibodies against non-overlapping epitopes
on
SARS-CoV-2.
"Generating
a
diversified
anti-target antibody panel
during the
discovery phase is key to a successful
therapeutic lead
campaign,
in particular for programs that are aimed at obtaining antibodies
with different
modes of action," stated ImmunoPrecise
President and CEO, Dr. Jennifer Bath. Leveraging
our
robust target-enrichment antibody
discovery technologies,
B
cell Select™ and
DeepDisplay™,
we
discovered a
highly sequence diverse pool of anti-target antibodies, which
allows proper
down-selection
of
the
best-performing lead candidates for further development, thereby
increasing the chance of successful clinical
application."
About
B cell
Select™
IPA's B cell Select™ platform enables the
interrogation of a greater diversity of an antibody repertoire. By
interrogating isolated B cells, IPA can analyze full
organism repertoires with very little manipulation. This
proprietary platform is species independent allowing for the
generation of antibodies from samples not possible using other
methods. B cell Select™ has the potential to
develop
antibodies from any species (including humans) as well as from any
tissue. As the platform explores the entire antibody repertoire,
it provides the opportunity
to develop antibodies for anything that
is possible in an animal's immune repertoire including any protein
class, complex therapeutic targets, post-translational
modifications, and small molecules.
The B cell Select™ platform enables the
interrogation of 10 million blood cells to generate native
monoclonal antibodies from immunized animals that
specifically target an antigen. The B cell
Select™ process takes place early in
the antibody development process allowing for the rapid selection
of top candidates, drastically increasing the success rate of
antibody discovery. The platform also harnesses the power of the
immune system to generate natural pairing of the antibodies
produced by selected B cells.
About
DeepDisplay™
IPA's DeepDisplay™
is a phage
display approach based on building custom immune libraries from
multiple species, including transgenic animals, or the selection of
antigen-specific recombinant antibody fragments from our
proprietary human or llama phage libraries. Our libraries have been
made from human patient and naïve (scFv) repertoires, as well as
from naïve llama (VHH) repertoires. Custom immune libraries are
prepared from blood, spleen, lymph nodes, and bone marrow of
immunized animals or humans and capture the entire immune
repertoire for panning, rescue, and identification of unique
antibodies with pre-specified characteristics.
About
ImmunoPrecise
Antibodies
Ltd.
IPA is an innovation-driven,
technology platform company that supports its
pharmaceutical and biotechnology company partners in their quest to
discover and develop novel, therapeutic antibodies against all
classes of disease targets. The Company aims to
transform the conventional, multi-vendor, product development model
by bringing innovative and high-throughput, data-driven
technologies to its partners, incorporating the advantages of
diverse antibody repertoires with the Company's therapeutic
antibody discovery suite of technologies, to exploit antibodies of
broad epitope coverage, multiple antibody formats, valency and
size, and to discover antibodies against multiple/rare epitopes.
For further information, visit
www.immunoprecise.com or contact
solutions@immunoprecise.com.
Investor contact:
Frédéric
Chabot, Phone:
1-438-863-7071, Email: fchabot@immunoprecise.com
Forward
Looking Information
This news release contains
forward-looking statements within the meaning of applicable United
States securities laws and Canadian securities laws.
Forward-looking statements are often identified by the use of words
such as "potential", "plans", "expects" or "does not expect", "is
expected", "estimates", "intends", "anticipates" or "does not
anticipate", or "believes", or variations of such words and phrases
or state that certain actions, events or results "may", "could",
"would", "might" or "will" be taken, occur or be achieved.
Forward-looking information contained in this news release include,
but are not limited to, statements regarding the potential of
IPA's a TATX-112 for use in oncology or
neurodegenerative diseases (including the potential to
increase the therapeutic window by lowering the potential risk of
side effects and increasing efficacy against
tumors and
otherwise providing a higher safety profile than less-selective
small molecules), the potential for TATX-03 to be used against
SARS-CoV-2 and the potential of our B cell Select™ and
DeepDisplay™
platforms. In respect of the
forward-looking information contained herein, the Company has
provided such statements and information in reliance on certain
assumptions that management believed to be reasonable at the
time.
Forward-looking information
involves known and unknown risks, uncertainties and other factors
which may cause the actual results, performance or achievements
stated herein to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information. Actual results could differ materially
from those currently anticipated due to a number of factors and
risks, including, without limitation, TATX-112 and TATX-03 and
have not yet been
tested in humans and the Company may not be
successful in developing those antibody cocktails or
others developed using its B cell Select™ and
DeepDisplay™
platforms through the successful and
timely completion of preclinical assays, studies and clinical
trials, or may not receive all regulatory approvals to commence and
then continue clinical trials of its products, and, to be
successful in partnering or commercializing its
products,
the coverage and applicability of the Company's intellectual
property rights to its antibodies, as well as those risks
discussed in the Company's Annual Information Form dated November
16, 2020 (which may be viewed on the Company's profile at
www.sedar.com) and the Company's Form 40-F
dated December 28, 2020 (which may be viewed on the Company's
profile at
www.sec.gov). Should one or more of these
risks or uncertainties materialize, or should assumptions
underlying the forward-looking statements prove incorrect, actual
results, performance, or achievements may vary materially from
those expressed or implied by the forward-looking statements
contained in this news release. Accordingly, readers should not
place undue reliance on forward-looking information contained in
this news release. The forward-looking
statements contained in this news release are made as of the date
of this release and, accordingly, are subject to change after such
date. The Company does not assume any obligation to update or
revise any forward-looking statements, whether written or oral,
that may be made from time to time by us or on our behalf, except
as required by applicable law. Neither the TSX Venture
Exchange nor its Regulation Services Provider (as that term is
defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release
SOURCE ImmunoPrecise Antibodies
ImmunoPrecise Antibodies (TSXV:IPA)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
ImmunoPrecise Antibodies (TSXV:IPA)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
